Publication of supplement to prospectus

Oncology Venture Sweden AB (”Oncology Venture”) hereby publish a supplement to the prospectus due to the press releases the company published on March 21st 2017, March 24th 2017, March 28th 2017 and March 29th 2017, after the approval of the company’s prospectus by the Swedish Financial Supervisory Authority before Oncology Venture’s rights issue with subscription period on March 16th-30th 2017. The supplement to the prospectus is available on the company’s (www.oncologyventure.com), Sedermera Fondkommission’s (www.sedermera.se) and AktieTorget’s (www.aktietorget.se) respective websites.

For further information, please contact:

Ulla Hald Buhl, COO and
Chief IR & Communications
Mobile: +45 2170 1049
E-mail:uhb@oncologyventure.com 
           Or         Peter Buhl Jensen, CEO
Mobile: +45 21 60 89 22
E-mail: pbj@oncologyventure.com  

This information is information that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on March 29, 2017.

About Oncology Venture Sweden AB 

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient. The current product portfolio: LiPlaCis for Breast Cancer, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma. Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women’s cancers with a pipeline of three promising phase 2 product candidates and Danish OV-SPV 2 will test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor. 

Subscribe

Documents & Links